Antidote Treatment Nerve Agent Auto-Injector (ATNAA)
Closed Pre-Solicitation Posted
Not the latest version. See the latest pre-solicitation from .
- Solicitation number
- SPE2DP-23-R-0002
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Philadelphia, Pennsylvania 19111, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
Paragraph 1:
The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA), which contains Pralidoxime Chloride Injection and Atropine Injection in a dual chambered nose-pressure-activated automatic injector. The solicitation, Solicitation Number SPE2DP-23-R-0002, will be issued under the authority of 10 U.S.C. 2304(c)(1) and will be for a firm-fixed price, indefinite delivery, indefinite quantity contract with a base year and four one-year options. The quantities for the base year and each option year are a minimum of 225,000 and a maximum of 1,000,000 units. The successful contractor must have FDA approval to sell ATNAA before award.
Paragraph 2:
This procurement does not have a set-aside designation. The NAICS code is not provided, but the PSC code is 6505 - Medical and Surgical Instruments, Equipment, and Supplies. The current incumbent or contractors are not named. The budget range is not specified, but the minimum total quantity across the base year and four option years is 1,125,000 units and the maximum is 5,000,000 units. The production lead time is 164 days after the issuance date of the delivery order.
Notice text
2 versions
Update #2 · Latest ·
Solicitation: SPE2DP-23-R-0002
Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL
NSN: 6505-01-362-7427
Description:
The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019.
The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1).
The Government does not intend to use Part 12 for this acquisition – per FAR 10.002(d)(2).
The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of a base year and four (4) one-year options. The quantities for the base year and each option year are a minimum of 225,000 each and a maximum of 1,000,000 each.
Inspection/Acceptance at Destination
FOB Destination
Delivery Destination: Susquehanna, PA
Production Lead Time is 164 days after issuance date of the delivery order (DD1155).
All responsible sources may submit a proposal and shall be considered by the Agency.
The successful contractor shall have FDA approval to sell ATNAA before award decision.
****************************************************************************
IMPORTANT NOTICES
Availability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-23-R-0002 is expected to be issued on or around May 2024.
******************************************************************************
Update #1 ·
Solicitation: SPE2DP-23-R-0002
Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL
NSN: 6505-01-362-7427
Description:
The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019.
The Solicitation will be issued under authority 10 U.S.C. 2304(c)(1).
The Government does not intend to use Part 12 for this acquisition – per FAR 10.002(d)(2).
The proposed contract will be a firm-fixed price, indefinite delivery, indefinite quantity type contract. The contract will consist of a base year and four (4) one-year options. The quantities for the base year and each option year are a minimum of 225,000 each and a maximum of 1,000,000 each.
Inspection/Acceptance at Origin
FOB Destination
Delivery Destination: Susquehanna, PA
Production Lead Time is 164 days after issuance date of the delivery order (DD1155).
All responsible sources may submit a proposal and shall be considered by the Agency.
The successful contractor shall have FDA approval to sell ATNAA before award decision.
****************************************************************************
IMPORTANT NOTICES
Availability of solicitations, FAR 5.102(d) applies, as our office no longer issues solicitations or amendments in paper form. Offeror should register to receive notification of this solicitation or solicitation amendments. The solicitation will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Detailed system requirements and instructions for registration can be found on the DLA DIBBS Home Page accessed on https://www.dibbs.bsm.dla.mil/. Once the solicitation is posted, it will be available for viewing on DIBBS. From the DIBBS homepage, select "Solicitations" from the top bar to search for the solicitation. DIBBS Help can be accessed from the DIBBS homepage. Interested parties are further advised to set up automated notifications of solicitation changes through this website. Solicitation SPE2DP-23-R-0002 is expected to be issued on or around May 2024.
******************************************************************************
Files
| File | Type | Posted |
|---|---|---|
| ATNAA_MPID_6_2MAY2019.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Atnaa | Pre-Solicitation | |
| Antidote Treatment Nerve Agent Auto-Injector (ATNAA) | Limited / Sole Source Justification | |
| This notice | Pre-Solicitation | |
| Antidote Treatment Nerve Agent Auto-Injector (ATNAA) | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Epinephrine Injector | Medical Supply Chain | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity